NuBCP-9,a peptide that can bind Bcl-2 and convert its anti-apoptosis function,was reported to play an important role in cancer therapy [1].Mesoporous silica nanoparticles(MSNs)with the high payload and controlled release features were demonstrated to be excellent nanocarriers for anticancer drugs [2].In this present study,we aimed at fabricating folic acid(FA)-modified MSNs@NuBCP-9 delivery platform for specific targeting and intracellular release of NuBCP-9.